LAG-3 expression in tumor microenvironment of triple-negative breast cancer
Turkish Journal of Medical Sciences · 01.01.2023 · 53 (1) · 142-148
DOI: 10.55730/1300-0144.5567 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 01.01.2023. Verfasst von Gözde Tahtacı und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/aim: This study aimed to evaluate the expression of lymphocyte activation gene-3 (LAG-3) and its relationship with programmed cell death ligand-1 (PD-L1) in triple-negative breast cancer (TNBC). Materials and methods: LAG-3 and PD-L1 was evaluated in tumor-infiltrating lymphocytes (TILs) using immunohistochemistry (IHC). The chi-square test was used to estimate the associations between LAG-3, PD-L1 and clinicopathological characteristics. Correlation between LAG-3 stromal TIL (sTIL), LAG-3 intraepitelial TIL (iTIL) and PD-L1 was assessed with using the Spearman's correlation coefficient. Survival analysis was performed using the Kaplan-Meier method.
Results
The percentages of LAG-3 sTIL+, LAG-3 iTIL+, PD-L1+ tumor cells and PD-L1+ inflammatory cells were 52%, 42%, 14% and 70%, respectively. A strong positive correlation between LAG-3 sTIL and LAG-3 iTIL (r = 0.874, p < 0.001) and a moderate positive correlation between LAG-3 sTIL and PD-L1 (r = 0.584, p < 0.001) were found. LAG-3 and PD-L1 status did not significantly affect overall survival (OS) (HR: 0.56 (95% CI: 0.15-2.11) (p = 0.397), HR: 2.70 (95% CI: 0.56-13.02) (p = 0.215), respectively).
Conclusion
High levels of LAG-3 and PD-L1 expression were detected in patients with TNBC. Although their contribution to survival could not be determined, the high expression rates of PD-L1 and LAG-3 may help identify the subgroup of TNBC that would benefit from immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
- Department of Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey.
- Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey.
Zitieren
APA
Tahtacı, G., Günel, N., Sadioğlu, A., Akyürek, N., Boz, O., & Üner, A. (2023). LAG-3 expression in tumor microenvironment of triple-negative breast cancer. Turkish Journal of Medical Sciences, 53(1), 142-148. https://doi.org/10.55730/1300-0144.5567
Vancouver
Tahtacı G, Günel N, Sadioğlu A, Akyürek N, Boz O, Üner A. LAG-3 expression in tumor microenvironment of triple-negative breast cancer. Turkish Journal of Medical Sciences. 2023;53(1):142-148. doi:10.55730/1300-0144.5567
BibTeX
@article{Tahtac2023,
author = {Tahtacı, Gözde and Günel, Nazan and Sadioğlu, Aysu and Akyürek, Nalan and Boz, Oğulcan and Üner, Aytuğ},
title = {LAG-3 expression in tumor microenvironment of triple-negative breast cancer},
journal = {Turkish Journal of Medical Sciences},
year = {2023},
volume = {53},
number = {1},
pages = {142--148},
doi = {10.55730/1300-0144.5567}
}
EUVIMED